سعر نيوبوجن 30 مليون وحدة دولية سرنجة معبأة مسبقاً 30 MIU/0.5 مل 2025

Neupogen 30 MIU/0.5 ml prefilled syringe (Amgen > Multipharma, Egypt): filgrastim (r-metHuG-CSF) for neutropenia-related indications.

• Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs.Population: Adults and pediatric patientsDailyMed (NLM)
• Reduce the time to neutrophil recovery and duration of fever following induction or consolidation chemotherapy in patients with acute myeloid leukemia.Population: Patients with AMLDailyMed (NLM)
• Reduce the duration of neutropenia and neutropenia-related sequelae in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.Population: Patients undergoing BMTDailyMed (NLM)

• Most common adverse reactions in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy (≥5% difference vs placebo): pyrexia, pain, rash, cough and dyspnea.International label, equivalent formulation · DailyMed (NLM)
• Most common adverse reaction in patients undergoing PBPC mobilization and collection: bone pain.International label, equivalent formulation · DailyMed (NLM)

• Patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim or pegfilgrastim products.International label, equivalent formulation · DailyMed (NLM)

• Splenic rupture, including fatal cases: evaluate patients reporting left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.International label, equivalent formulation · DailyMed (NLM)
• Acute respiratory distress syndrome: evaluate patients who develop fever, lung infiltrates or respiratory distress; discontinue in patients with ARDS.International label, equivalent formulation · DailyMed (NLM)
• Serious allergic reactions including anaphylaxis: permanently discontinue in patients with serious allergic reactions.International label, equivalent formulation · DailyMed (NLM)

• Although available data with filgrastim use in pregnant women are insufficient to establish whether there is a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes, available published data have not established an association with these outcomes.International label, equivalent formulation · DailyMed (NLM)
• There are published reports of filgrastim transfer into human milk; consider the developmental and health benefits of breastfeeding with the mother's clinical need for filgrastim and any potential adverse effects on the breastfed child.International label, equivalent formulation · DailyMed (NLM)

• Filgrastim: Colony-stimulating factors act on hematopoietic cells by binding to specific cell-surface receptors, stimulating proliferation, differentiation commitment and some end-cell functional activation; filgrastim mainly affects neutrophil production and function (US Neupogen label 12.1).